BACKGROUND: Aerodynamic forces provide the primary means of distributing aerosol medications within the lungs. Partial airway obstructions can limit both air flow and aerosol penetration into diseased zones. We hypothesize that low surface tension additives may help to disperse aerosol medications after deposition in the airways, improving dose uniformity and drug delivery to underventilated regions. To test this, we performed a pilot scintigraphy study of surfactant and saline deposition and postdeposition dispersion. METHODS: Because inhaled antibiotics for cystic fibrosis provide an example of where self-dispersing medications may be useful, we administered calfactant and saline aerosols with added Technetium 99m sulfur colloid (Tc-SC; 100 nm filtered) on different days in randomized order to eight cystic fibrosis (CF) subjects (average FEV(1)%, p=85 ± 12%). Nebulized delivery was matched (similar aerosol sizes and volume delivery rates, fixed breathing patterns). Tc-SC distribution in the lungs was imaged continuously for 30 min after delivery. RESULTS: Both aerosols were well tolerated. Aerosol distribution was mostly peripheral (58/42%) and initially similar for saline and surfactant. Changes in whole lung counts after 30 min were also similar. Peripheral lung activity decreased more rapidly on average with calfactant though the difference versus saline was not statistically significant. Central to peripheral count ratio decreased with saline and increased with calfactant and c/p changes approached significance (-0.05 ± 0.16 vs. 0.10 ± 0.10; p=0.07 Wilcoxon). CONCLUSIONS: Our results lack statistical significance, but suggest that inhaled calfactant increased peripheral clearance, due to either surfactant-based dispersion or mucociliary effects. Further studies are needed to define the potential for low surface tension carriers to improve drug delivery.
RCT Entities:
BACKGROUND: Aerodynamic forces provide the primary means of distributing aerosol medications within the lungs. Partial airway obstructions can limit both air flow and aerosol penetration into diseased zones. We hypothesize that low surface tension additives may help to disperse aerosol medications after deposition in the airways, improving dose uniformity and drug delivery to underventilated regions. To test this, we performed a pilot scintigraphy study of surfactant and saline deposition and postdeposition dispersion. METHODS: Because inhaled antibiotics for cystic fibrosis provide an example of where self-dispersing medications may be useful, we administered calfactant and saline aerosols with added Technetium 99m sulfur colloid (Tc-SC; 100 nm filtered) on different days in randomized order to eight cystic fibrosis (CF) subjects (average FEV(1)%, p=85 ± 12%). Nebulized delivery was matched (similar aerosol sizes and volume delivery rates, fixed breathing patterns). Tc-SC distribution in the lungs was imaged continuously for 30 min after delivery. RESULTS: Both aerosols were well tolerated. Aerosol distribution was mostly peripheral (58/42%) and initially similar for saline and surfactant. Changes in whole lung counts after 30 min were also similar. Peripheral lung activity decreased more rapidly on average with calfactant though the difference versus saline was not statistically significant. Central to peripheral count ratio decreased with saline and increased with calfactant and c/p changes approached significance (-0.05 ± 0.16 vs. 0.10 ± 0.10; p=0.07 Wilcoxon). CONCLUSIONS: Our results lack statistical significance, but suggest that inhaled calfactant increased peripheral clearance, due to either surfactant-based dispersion or mucociliary effects. Further studies are needed to define the potential for low surface tension carriers to improve drug delivery.
Authors: Alan J Nimmo; Jill R Carstairs; Sanjay K Patole; John Whitehall; Kate Davidson; Robert Vink Journal: Clin Exp Pharmacol Physiol Date: 2002-08 Impact factor: 2.557
Authors: Amy L Marcinkowski; Stephen Garoff; Robert D Tilton; Joseph M Pilewski; Timothy E Corcoran Journal: J Aerosol Med Pulm Drug Deliv Date: 2008-12 Impact factor: 2.849
Authors: Kevin Koch; Beautia Dew; Timothy E Corcoran; Todd M Przybycien; Robert D Tilton; Stephen Garoff Journal: Mol Pharm Date: 2011-01-20 Impact factor: 4.939
Authors: Scott H Donaldson; William D Bennett; Kirby L Zeman; Michael R Knowles; Robert Tarran; Richard C Boucher Journal: N Engl J Med Date: 2006-01-19 Impact factor: 91.245
Authors: Christian A Merlo; Michael P Boyle; Marie Diener-West; Bruce C Marshall; Christopher H Goss; Noah Lechtzin Journal: Chest Date: 2007-07-23 Impact factor: 9.410
Authors: Ramankur Sharma; Amsul Khanal; Timothy E Corcoran; Stephen Garoff; Todd M Przybycien; Robert D Tilton Journal: J Aerosol Med Pulm Drug Deliv Date: 2015-03-10 Impact factor: 2.849
Authors: Steven V Iasella; Ningguan Sun; Xin Zhang; Timothy E Corcoran; Stephen Garoff; Todd M Przybycien; Robert D Tilton Journal: J Colloid Interface Sci Date: 2019-06-06 Impact factor: 8.128
Authors: Amy Z Stetten; Steven V Iasella; Timothy E Corcoran; Stephen Garoff; Todd M Przybycien; Robert D Tilton Journal: Curr Opin Colloid Interface Sci Date: 2018-01-13 Impact factor: 6.448
Authors: Ramankur Sharma; Timothy E Corcoran; Stephen Garoff; Todd M Przybycien; Ellen R Swanson; Robert D Tilton Journal: ACS Appl Mater Interfaces Date: 2013-06-10 Impact factor: 9.229
Authors: Steven V Iasella; Amy Z Stetten; Timothy E Corcoran; Stephen Garoff; Todd M Przybycien; Robert D Tilton Journal: J Aerosol Med Pulm Drug Deliv Date: 2017-10-20 Impact factor: 2.849